Table 3

Logistic regression analysis to determine the prognostic effects of selected variables on vision maintenance (loss of <15 letters) at (A) year 1 and (B) year 2

CoefficientSELower 95% CIUpper 95% CIp Value
(A) Variables (year 1)
Country
 Canada1.251.320.169.850.83
 France0.710.740.095.420.74
 Germany0.780.820.106.120.82
 Ireland1.661.860.1914.910.65
 Italy0.910.940.126.910.93
 The Netherlands1.221.270.169.400.85
 UK1.211.270.159.430.86
Reimbursement type
 Individual0.710.230.381.330.28
 National standard0.790.190.491.260.32
 Separate contract0.400.310.091.820.23
 Patient0.731.280.0222.900.86
 Unknown1.410.890.414.870.59
 Other0.570.620.074.730.60
Age at start of therapy0.970.010.950.98<0.001
Baseline visual acuity score0.970.000.960.98<0.001
Number of injections (ranibizumab)0.940.030.880.990.03
Switch to other treatments0.860.230.511.440.56
Number of ophthalmoscopies and OCT (combined)1.030.021.001.060.03
(B) Variables (year 2)
Country
 Canada0.590.640.075.030.63
 France0.860.920.117.020.89
 Germany0.600.660.075.160.65
 Ireland0.961.170.0910.520.97
 Italy0.981.050.128.040.99
 The Netherlands1.511.640.1812.600.70
 UK1.171.280.149.970.89
Reimbursement type*
 Individual0.880.340.411.880.74
 National standard0.740.210.431.290.29
 Separate contract0.100.110.010.930.04
 Unknown0.630.530.123.230.58
 Other0.420.480.043.940.45
Age at start of therapy0.960.010.940.98<0.001
Baseline visual acuity score0.970.010.960.97<0.001
Number of monitoring visits0.970.020.941.010.13
Number of injections (ranibizumab)1.000.020.971.040.85
Number of ophthalmoscopies and OCT (combined)1.020.011.001.040.02
  • *Reimbursement patient category dropped because of colinearity.

  • OCT, optical coherence tomography.